Liver transplantation (LT) is the second most performed solid organ transplant. Coronary artery disease (CAD) is a critical consideration for LT candidacy, particularly in patients with known CAD or risk factors, including metabolic dysfunction associated with steatotic liver disease. The presence of severe CAD may exclude patients from LT; therefore, precise preoperative evaluation and interventions are necessary to achieve transplant candidacy. Cardiovascular complications represent the earliest nongraft-related cause of death post-transplantation. Timely intervention to reduce cardiovascular events depends on adequate CAD screening. Coronary disease screening in end-stage liver disease is challenging because standard noninvasive CAD screening tests have low sensitivity due to hyperdynamic state and vasodilatation. As a result, there is overuse of invasive coronary angiography to exclude severe CAD. Coronary artery calcium scoring using a computed tomography scan is a tool for the prediction of cardiovascular events, and can be used to achieve risk stratification in LT candidates. Recent literature shows that qualitative assessment on both noncontrast- and contrast-enhanced chest computed tomography can be used instead of calcium score to assess the presence of coronary calcium. With increasing prevalence, protocols to address CAD in LT candidates must be reconsidered. Percutaneous coronary intervention could allow a shorter duration of dual-antiplatelet therapy in simple lesions, with safer perioperative outcomes. Hybrid coronary revascularization is an option for high-risk LT candidates with multivessel disease nonamenable to percutaneous coronary intervention. The objective of this review is to evaluate existing methods for preoperative cardiovascular risk stratification, and to describe interventions before surgery to optimize patient outcomes and reduce cardiovascular event risk., Competing Interests: Declaration of competing interest Piroze Davierwala, MD: Medtronic Inc, Speaker's bureau. Sanjog Kalra, MD, MSc: Abiomed, Speaker's Bureau, advisory board participation, sponsored research participant, consultant. Boston Scientific: Proctor, consultant, speaker's bureau, advisory board, sponsored research participant. Philips Healthcare: Proctor, speaker's bureau, advisory board participation, sponsored research participant, consultant. Cardiovascular Systems Inc: Proctor, speaker's bureau, consultant. Translumina Therapeutics: Speaker's bureau, proctor, consultant. Medtronic Inc: Speaker's bureau, advisory board. Avinger Inc: Medical advisory board., (Copyright © 2023 Elsevier Inc. All rights reserved.)